Shares in Californian rare disease company Reneo Pharmaceuticals have plummeted after the firm announced the failure of its pivotal STRIDE study. 15 December 2023
Former Novartis executive James Bradner has joined Amgen (Nasdaq: AMGN) as executive vice president of research and development (R&D), and chief scientific offi 14 December 2023
Britain’s largest drugmaker, AstraZeneca, has announced positive long-term results from the Phase III ALPHA trial at the annual meeting of the American Society 11 December 2023
The National Institute for Health and Care Excellence (NICE) has opted against recommending Crysvita (burosumab) to treat adults in England and Wales who have a 29 November 2023
Shares of Dutch immunology specialist Argenx (Euronext: ARGX) have dropped around a tenth following negative results from the ADVANCE-SC study. 29 November 2023
The European Medicines Agency (EMA) has validated Vertex’s Type II variation application to the Marketing Authorization for Kaftrio (ivacaftor/tezacaftor/elexac 24 November 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.